Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CYFRA 21.1' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 165 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Gadducci, A; Ferdeghini, M; Cosio, S; Fanucchi, A; Cristofani, R; Genazzani, AR
      The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    2. Nap, M; van Wel, T; Andres, C; Bellanger, L; Bodenmuller, H; Bonfrer, H; Brundell, J; Einarsson, R; Erlandsson, A; Johansson, A; Leca, JF; Meier, T; Seguin, P; Sjodin, A; Stigbrand, T; Sundstrom, BE; van Dalen, A; Wiebelhaus, E; Wiklund, B; Hilgers, J
      Immunohistochemical profiles of 30 monoclonal antibodies against cytokeratins 8, 18 and 19 - Second report of the TD5 workshop

      TUMOR BIOLOGY
    3. Miedouge, M; Devys, A; Simon, M; Rouzaud, P; Salama, G; Reyre, J; Pujazon, MC; Carles, P; Serre, G
      High levels of cytokeratin 19 fragments but no evidence of cytokeratins 1,2, 10/11, 14 or filaggrin in the serum of squamous cell lung carcinoma patients

      TUMOR BIOLOGY
    4. Banal, A; Hacene, K; Berthelot-Ruff, E; Mahe, E; Fontana, X; Pichon, MF
      Comparison of Cyfra 21-1 and SCC assays in head and neck tumours

      TUMOR BIOLOGY
    5. Mady, EA
      Cytokeratins as serum markers in Egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS

      INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
    6. Karnak, D; Ulubay, G; Kayacan, O; Beder, S; Ibis, E; Oflaz, G
      Evaluation of Cyfra 21-1: A potential tumor marker for non-small cell lungcarcinomas

      LUNG
    7. Molinari, N; Daures, JP; Durand, JF
      Regression splines for threshold selection in survival data analysis

      STATISTICS IN MEDICINE
    8. Ando, S; Kimura, H; Iwai, N; Nomoto, Y; Shima, M; Ando, M; Kuriyama, T
      Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer

      ANTICANCER RESEARCH
    9. Cioffi, M; Vietri, MT; Gazzerro, P; Magnetta, R; D'Auria, A; Durante, A; Nola, E; Puca, GA; Molinari, AM
      Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers

      LUNG CANCER
    10. Vassilakopoulos, T; Troupis, T; Sotiropoulou, C; Zacharatos, P; Katsaounou, P; Parthenis, D; Noussia, O; Troupis, G; Papiris, S; Kittas, C; Roussos, C; Zakynthinos, S; Gorgoulis, V
      Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer

      LUNG CANCER
    11. Pujol, JL; Boher, JM; Grenier, J; Quantin, X
      Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients

      LUNG CANCER
    12. Alatas, F; Alatas, O; Metintas, M; Colak, O; Harmanci, E; Demir, S
      Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions

      LUNG CANCER
    13. Boman, H; Hedelin, H; Holmang, S
      Urine tissue-polypeptide-specific antigen (TPS) as a marker for bladder cancer

      SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
    14. Giannopoulos, A; Manousakas, T; Gounari, A; Constantinides, C; Choremi-Papadopoulou, H; Dimopoulos, C
      Comparative evaluation of the diagnostic performance of the BTA stat test,NMP22 and urinary bladder cancer antigen for primary and recurrent bladdertumors

      JOURNAL OF UROLOGY
    15. Dohmoto, K; Hojo, S; Fujita, J; Yang, Y; Ueda, Y; Bandoh, S; Yamaji, Y; Ohtsuki, Y; Dobashi, N; Ishida, T; Takahara, J
      The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines

      INTERNATIONAL JOURNAL OF CANCER
    16. Paganuzzi, M; Onetto, M; Marroni, P; Filiberti, R; Tassara, E; Parodi, S; Felletti, R
      Diagnostic value of CYFRA 21-1 turner marker end CEA in pleural effusion due to mesothelioma

      CHEST
    17. Sanchez-Carbayo, M; Urrutia, M; de Buitrago, JMG; Navajo, JA
      Utility of serial urinary tumor markers to individualize intervals betweencystoscopies in the monitoring of patients with bladder carcinoma

      CANCER
    18. Lee, JK; Hsieh, JF; Tsai, SC; Ho, YJ; Sun, SS; Kao, CH
      Comparison of cyfra 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma

      ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY
    19. Barth, Z; Kohler, B
      An unusual cause of malignant ascites - Peritoneal mesothelioma - Reply

      DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
    20. Sanchez-Carbayo, M; Urrutia, M; de Buitrago, JMG; Navajo, JA
      Evaluation of two new urinary tumor markers: Bladder tumor fibronectin andcytokeratin 18 for the diagnosis of bladder cancer

      CLINICAL CANCER RESEARCH
    21. Ahmed, FE
      Molecular markers for early cancer detection

      ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS-PART C OF JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH
    22. Yazigi, R; Castillo, R; Aliste, G; Garrido, J; Opazo, A; Prado, S; Navarro, C; Altieri, E; Del Campo, G
      Cyfra 21-1 marker in carcinoma of the cervix

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    23. Einarsson, R
      Cytokeratins as tumor markers - Molecular and clinical data with focus on TPS

      JOURNAL OF TUMOR MARKER ONCOLOGY
    24. Nisman, B; Heching, N; Barak, V
      Serum tumor markers in resectable and non-resectable non-small cell lung cancer

      JOURNAL OF TUMOR MARKER ONCOLOGY
    25. Pujol, JL; Greiner, J; Boher, JM; Quantin, X; Parrat, E; Daures, JP
      New data regarding serum markers in lung cancer.

      REVUE DES MALADIES RESPIRATOIRES
    26. Tas, F; Aydiner, A; Topuz, E; Yasasever, V; Karadeniz, A; Saip, P
      Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer

      JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
    27. Sun, SS; Hsieh, JF; Tsai, SC; Ho, YJ; Lee, JK; Kao, CH
      Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    28. Brockmann, JG; St Nottberg, H; Glodny, B; Sprakel, B; Senninger, N
      Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer

      ANTICANCER RESEARCH
    29. Kulpa, J; Wojcik, E; Radkowski, A; Kolodziejski, L; Stasik, Z
      CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lungcancer and in chemical industry workers as a reference group

      ANTICANCER RESEARCH
    30. Maass, JD; Hoffmann-Fazel, A; Goeroegh, T; Hoffmann, M; Meyer, JE; Gottschlich, S; Rudert, H; Maune, S
      Cyfra 21-1: a serological help for detection of distant metastases in headand neck cancer

      ANTICANCER RESEARCH
    31. Suzuki, Y; Nakano, T; Ohno, T; Abe, A; Morita, S; Tsujii, H
      Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    32. Kim, YC; Lim, SC; Bom, HS; Park, KO; Na, KJ; Park, HK; Hwang, JH
      Different cutoff values of Cyfra 21-1 for cavitary and noncavitary lung cancers

      LUNG CANCER
    33. Buccheri, G; Ferrigno, D
      Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer:a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase

      LUNG CANCER
    34. Dohmoto, K; Hojo, S; Fujita, J; Ueda, Y; Bandoh, S; Yamaji, Y; Ohtsuki, Y; Dobashi, N; Takahara, J
      Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines

      LUNG CANCER
    35. Gonzalez-Quintela, A; Mella, C; Perez, LF; Abdulkader, I; Caparrini, AM; Lojo, S
      Increased serum tissue polypeptide specific antigen (TPS) in alcoholics: Apossible marker of alcoholic hepatitis

      ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
    36. Gaarenstroom, KN; Kenter, GG; Bonfrer, JMG; Korse, CM; Van de Vijver, MJ; Fleuren, GJ; Trimbos, JB
      Can initial serum Cyfra 21-1, SCC antigen, and TPA levels in squamous cellcervical cancer predict lymph node metastases or prognosis?

      GYNECOLOGIC ONCOLOGY
    37. Mungan, NA; Vriesema, JLJ; Thomas, CMG; Kiemeney, LALM; Witjes, JA
      Urinary bladder cancer test: A new urinary tumor marker in the follow-up of superficial bladder cancer

      UROLOGY
    38. Sanchez-Carbayo, M; Urrutia, M; Silva, JM; Romani, R; Garcia, J; Alferez, F; de Buitrago, JMG; Navajo, JA
      Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer

      UROLOGY
    39. Regauer, S; Beham, A; Mannweiler, S
      CK7 expression in carcinomas of the Waldeyer's ring area

      HUMAN PATHOLOGY
    40. Watine, J
      Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review

      SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
    41. Tempfer, CB; Bancher-Todesca, D; Zeisler, H; Schatten, C; Husslein, P; Gregg, AR
      Placental expression and serum concentrations of cytokeratin 19 in preeclampsia

      OBSTETRICS AND GYNECOLOGY
    42. Riantawan, P; Sangsayan, P; Bangpattanasiri, K; Rojanaraweewong, P
      Limited additive value of pleural fluid carcinoembryonic antigen level in malignant pleural effusion

      RESPIRATION
    43. Sanchez-Carbayo, M; Urrutia, M; Hernandez-Cereceno, ML; de Buitrago, JMG; Navajo, JA
      Cytokeratins (UBC and CYFRA 21-1) and molecular protein matrix as urinary tumor markers in the diagnosis of bladder cancer

      MEDICINA CLINICA
    44. Pariente, JL; Bordenave, L; Jacob, F; Gobinet, A; Leger, F; Ferriere, JM; Le Guillou, M
      Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer

      JOURNAL OF UROLOGY
    45. Fuhrman, C; Duche, JC; Chouaid, C; Abd Alsamad, I; Atassi, K; Monnet, I; Tillement, JP; Housset, B
      Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies

      CLINICAL BIOCHEMISTRY
    46. Kashiwabara, K; Nakamura, H; Esaki, T
      Prognosis in bronchogenic squamous cell carcinoma groups divided accordingto serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels

      CLINICA CHIMICA ACTA
    47. Kawaguchi, H; Ohno, S; Miyazaki, M; Hashimoto, K; Egashira, A; Saeki, H; Watanabe, M; Sugimachi, K
      CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma - Clinical utility for defection of recurrences

      CANCER
    48. Nakata, B; Ogawa, Y; Ishikawa, T; Ikeda, K; Kato, Y; Nishino, H; Hirakawa, K
      Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma

      CANCER
    49. Doweck, I; Barak, M; Uri, N; Greenberg, E
      The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease

      BRITISH JOURNAL OF CANCER
    50. Tsuchiya, Y; Onda, M; Miyashita, M; Sasajima, K
      Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stageand prognosis of squamous cell carcinoma of the oesophagus

      MEDICAL ONCOLOGY
    51. Dobashi, N; Fujita, J; Ohtsuki, Y; Yamadori, I; Yoshinouchi, T; Kamei, T; Takahara, J
      Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia

      EUROPEAN RESPIRATORY JOURNAL
    52. Lai, RS; Chen, CC; Lee, PC; Lu, JY
      Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion

      JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    53. Kao, CH; Hsieh, JF; Ho, YJ; Ding, HJ
      Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma

      LUNG
    54. Fujita, J; Dobashi, N; Tokuda, M; Bandoh, S; Ohtsuki, Y; Yamadori, I; Yoshinouchi, T; Ueda, Y; Takahara, J
      Elevation of cytokeratin 19 fragment in patients with interstitial pneumonia associated with polymyositis/dermatomyositis

      JOURNAL OF RHEUMATOLOGY
    55. Theyer, G; Durer, A; Theyer, U; Haberl, I; Ulsperger, E; Baumgartner, G; Hamilton, G
      Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgensuppression therapy

      PROSTATE
    56. Kao, CH; Hsieh, JF; Ho, YJ; Tsai, SC; Lee, JK
      Cytokeratin fragment 19 (CYFRA 21-1) in healthy smokers

      ANTICANCER RESEARCH
    57. Nisman, B; Amir, G; Lafair, J; Heching, N; Lyass, O; Peretz, T; Barak, V
      Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer

      ANTICANCER RESEARCH
    58. Foa, P; Fornier, M; Miceli, R; Seregni, E; Santambrogio, L; Nosotti, M; Cataldo, I; Sala, M; Caldiera, S; Bombardieri, E
      Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer

      ANTICANCER RESEARCH
    59. Stieber, P; Zimmermann, A; Reinmiedl, J; Muller, C; Hoffmann, H; Dienemann, H
      CYFRA 21-1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC)

      ANTICANCER RESEARCH
    60. Ebert, W; Muley, T
      CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy

      ANTICANCER RESEARCH
    61. Stieber, P; Dienemann, H; Schalhorn, A; Schmitt, UM; Reinmiedl, J; Hofmann, K; Yamaguchi, K
      Pro-gastrin-releasing peptide (ProGRP) - A useful marker in small cell lung carcinomas

      ANTICANCER RESEARCH

    62. Tumour markers in lung cancer: EGTM recommendations

      ANTICANCER RESEARCH
    63. Southgate, J; Harnden, P; Trejdosiewicz, LK
      Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications

      HISTOLOGY AND HISTOPATHOLOGY
    64. Seemann, MD; Beinert, T; Furst, H; Fink, U
      An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions

      LUNG CANCER
    65. Schouwink, H; Korse, CM; Bonfrer, JMG; Hart, AAM; Baas, P
      Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma

      LUNG CANCER
    66. Sanchez-Carbayo, M; Herrero, E; Megias, J; Mira, A; Soria, F
      Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder

      UROLOGY
    67. Sanchez-Carbayo, M; Herrero, E; Megias, J; Mira, A; Espasa, A; Chinchilla, V; Soria, F
      Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder

      JOURNAL OF UROLOGY
    68. Pina, TC; Zapata, IT; Lopez, JB; Perez, JL; Paricio, PP; Hernandez, PM
      Tumor markers in lung cancer: Does the method of obtaining the cut-off point and reference population influence diagnostic yield?

      CLINICAL BIOCHEMISTRY
    69. Kashiwabara, K; Nakamura, H; Esaki, T
      Serum cytokeratin 19 fragment levels in non-small cell lung cancer patients according to T factor in the TNM classification

      CLINICA CHIMICA ACTA
    70. Ferrer, J; Villarino, MA; Encabo, G; Felip, E; Bermejo, B; Vila, S; Orriols, R
      Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuronspecific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions

      CANCER
    71. Nagler, RM; Barak, M; Peled, M; Ben-Aryeh, H; Filatov, M; Laufer, D
      Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1and TPS in oral squamous cell carcinoma

      CANCER
    72. Miedouge, M; Rouzaud, P; Salama, G; Pujazon, MC; Vincent, C; Mauduyt, MA; Reyre, J; Carles, P; Serre, G
      Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions

      BRITISH JOURNAL OF CANCER
    73. Desgrandchamps, F; Teren, M; Dal Cortivo, L; Marolleau, JP; Bertheau, P; Villette, JM; Cortesse, A; Teillac, P; Le Duc, A; Hamdy, FC
      The effects of transurethral resection and cystoprostatectomy on dissemination of epithelial cells in the circulation of patients with bladder cancer

      BRITISH JOURNAL OF CANCER
    74. Boher, JM; Pujol, JL; Grenier, J; Daures, JP
      Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis

      BRITISH JOURNAL OF CANCER
    75. Lee, YC; Knox, BS; Garrett, JE
      Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions

      AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE
    76. Ogawa, T; Tsurusako, Y; Kimura, N; Nishioka, S; Akagi, H; Nishizaki, K; Nishioka, K; Rutka, J
      Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck

      ACTA OTO-LARYNGOLOGICA
    77. YUAN CC; HUANG TS; NG HT; LIU RS; HUNG MW; TSAI LC
      ELEVATED CYTOKERATIN-19 EXPRESSION ASSOCIATED WITH APOPTOTIC RESISTANCE AND MALIGNANT PROGRESSION OF HUMAN CERVICAL-CARCINOMA

      Apoptosis
    78. WATINE J; CHARET JC
      DO BLOOD-CELL COUNTS HAVE AN INDEPENDENT PROGNOSTIC VALUE IN PRIMARY LUNG-CANCER

      HEMATOLOGY AND CELL THERAPY
    79. HAMAKAWA H; BAO Y; TAKARADA M; FUKUZUMI M; TANIOKA H
      CYTOKERATIN EXPRESSION IN SQUAMOUS-CELL CARCINOMA OF THE LUNG AND ORAL CAVITY - AN IMMUNOHISTOCHEMICAL STUDY WITH POSSIBLE CLINICAL RELEVANCE

      Oral surgery, oral medicine, oral pathology, oral radiology and endodontics
    80. QUILLIEN V; RAOUL JL; LAURENT JF; MEUNIER B; LEPRISE E
      COMPARISON OF CYFRA-21-1, TPA AND SCC TUMOR-MARKERS IN ESOPHAGEAL SQUAMOUS-CELL CARCINOMA

      Oncology Reports
    81. STIGBRAND T; ANDRES C; BELLANGER L; OMARY MB; BODENMULLER H; BONFRER H; BRUNDELL J; EINARSSON R; ERLANDSSON A; JOHANSSON A; LECA JF; LEVI M; MEIER T; NAP M; NUSTAD K; SEGUIN P; SJODIN A; SUNDSTROM B; VANDALEN A; WIEBELHAUS E; WIKLUND B; ARLESTIG L; HILGERS J
      EPITOPE SPECIFICITY OF 30 MONOCLONAL-ANTIBODIES AGAINST CYTOKERATIN ANTIGENS - THE ISOBM TD5-1 WORKSHOP

      Tumor biology
    82. Torre, GC
      SCC antigen in malignant and nonmalignant squamous lesions

      TUMOR BIOLOGY
    83. KASHIHARA T; OHKI A; KOBAYASHI T; SATO T; NISHIZAWA H; OGAWA K; TAKO H; KAWAKAMI F; TSUJI M; TAMAOKA K
      INTRAHEPATIC CHOLANGIOCARCINOMA WITH INCREASED SERUM CYFRA-21-1 LEVEL

      Journal of gastroenterology
    84. Kashiwabara, K; Kishi, K; Nakamura, H; Yagyu, H; Kobayashi, K; Watanabe, O; Matsuoka, T
      Mechanism of increased serum cytokeratin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure

      INTERNAL MEDICINE
    85. Niklinski, J; Burzykowski, T; Niklinska, W; Laudanski, J; Chyczewski, L; Rapellino, M; Furman, M
      Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer

      EUROPEAN RESPIRATORY JOURNAL
    86. PUJOL JL; BOHER JM; GRENIER J; QUANTIN X; SAFFONT L; DAURES JP
      NEURON-SPECIFIC ENOLASE (NSE) IN THE SURVEILLANCE OF SMALL-CELL CANCERS - AN ASSESSMENT OF THE PROGNOSTIC INFORMATION USING MARKOVS MODEL

      Revue des maladies respiratoires
    87. CALLET N; LENIR CCS; BERTHELOT E; PICHON MF
      CANCER OF THE UTERINE CERVIX - SENSITIVITY AND SPECIFICITY OF SERUM CYFRA-21.1 DETERMINATIONS

      European journal of gynaecological oncology
    88. MARUKAWA M; HIYAMA J; SHIOTA Y; ONO T; SASAKI N; TANIYAMA K; MASHIBA H
      THE USEFULNESS OF CYFRA 21-1 IN DIAGNOSING AND MONITORING MALIGNANT PLEURAL MESOTHELIOMA

      Acta medica Okayama
    89. NISMAN B; BARAK V; HECHING N; KRAMER M; REINUS C; LAFAIR J
      CYTOKERATIN MARKERS IN MALIGNANT PLEURAL MESOTHELIOMA

      Cancer detection and prevention
    90. RAY P; QUANTIN X; GRENIER J; PUJOL JL
      PREDICTIVE FACTORS OF TUMOR RESPONSE AND PROGNOSTIC FACTORS OF SURVIVAL DURING LUNG-CANCER CHEMOTHERAPY

      Cancer detection and prevention
    91. YEN TC; LIN WY; KAO CH; CHENG KY; WANG SJ
      A STUDY OF A NEW TUMOR-MARKER, CYFRA-21-1, IN SQUAMOUS-CELL CARCINOMAOF THE HEAD AND NECK, AND COMPARISON WITH SQUAMOUS-CELL CARCINOMA ANTIGEN

      Clinical otolaryngology and allied sciences
    92. YANAGAWA H; SHIMADA K; TANAKA H; TAKEUCHI E; MANIWA K; SUZUKI Y; OGUSHI F; SANO N; IZUMI K; SONE S
      A CASE WITH SMALL-CELL CARCINOMA OF THE ESOPHAGUS - MEASUREMENT OF TUMOR-MARKERS, INCLUDING PRO-GASTRIN-RELEASING PEPTIDE

      Anticancer research
    93. FUJIWARA M; SATOH H; FUJIMOTO M; YAZAWA T; ISHIKAWA H; HORIGUCHI H; OGATA T; MATSUI M; KAMMA H
      LUNG-CANCER CELL-LINE PRODUCING CYTOKERATIN-19 FRAGMENT AND SIALYL-LEWIS X-I ANTIGEN

      Anticancer research
    94. VINOLAS N; MOLINA R; GALAN MC; CASAS F; CALLEJAS MA; FILELLA X; GRAU JJ; BALLESTA AM; ESTAPE J
      TUMOR-MARKERS IN RESPONSE MONITORING AND PROGNOSIS OF NONSMALL CELL LUNG-CANCER - PRELIMINARY-REPORT

      Anticancer research
    95. Hirashima, T; Takada, M; Komiya, T; Nitta, T; Masashi, K; Masuda, N; Matui, K; Kikui, M; Yasumitsu, T; Kawase, I
      Prognostic significance of CYFRA 21-1 in non-small cell lung cancer

      ANTICANCER RESEARCH
    96. KELLER T; BITTERLICH N; HILFENHAUS S; BIGL H; LOSER T; LEONHARDT P
      TUMOR-MARKERS IN THE DIAGNOSIS OF BRONCHIAL-CARCINOMA - NEW OPTIONS USING FUZZY LOGIC-BASED TUMOR-MARKER PROFILES

      Journal of cancer research and clinical oncology
    97. LIN WY; YEN TC; CHENG KY; WANG SJ
      THE VALUE OF CYFRA-21-1, A NEW TUMOR-MARKER, IN NASOPHARYNGEAL CARCINOMA

      Neoplasma
    98. KASHIWABARA K; NAKAMURA H; KIGUCHI T; MATSUOKA T
      CORRELATION BETWEEN SERUM CYTOKERATIN-19 FRAGMENT AND TISSUE POLYPEPTIDE ANTIGEN LEVELS IN PATIENTS WITH NONMALIGNANT DISEASES

      Clinica chimica acta
    99. NISMAN B; LAFAIR J; HECHING N; LYASS O; BARAS M; PERETZ T; BARAK V
      EVALUATION OF TISSUE POLYPEPTIDE SPECIFIC ANTIGEN, CYFRA-21-1, AND CARCINOEMBRYONIC ANTIGEN IN NONSMALL CELL LUNG-CARCINOMA - DOES THE COMBINED USE OF CYTOKERATIN MARKERS GIVE ANY ADDITIONAL INFORMATION

      Cancer
    100. TEMPFER C; HEFLER L; HEINZL H; LOESCH A; GITSCH G; RUMPOLD H; KAINZ C
      CYFRA-21-1 SERUM LEVELS IN WOMEN WITH ADNEXAL MASSES AND INFLAMMATORYDISEASES

      British Journal of Cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/05/20 alle ore 20:14:26